Generation of iPSCs from cultured human malignant cells
Author(s) -
Jan E. Carette,
Jan Pruszak,
Malini Varadarajan,
Vincent A. Blomen,
Sumita Gokhale,
Fernando D. Camargo,
Marius Wernig,
Rudolf Jaenisch,
Thijn R. Brummelkamp
Publication year - 2010
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood-2009-07-231845
Subject(s) - biology , induced pluripotent stem cell , cancer research , myeloid leukemia , stem cell , reprogramming , imatinib , cellular differentiation , myeloid , cell culture , microbiology and biotechnology , cell , embryonic stem cell , genetics , gene
Induced pluripotent stem cells (iPSCs) can be generated from various differentiated cell types by the expression of a set of defined transcription factors. So far, iPSCs have been generated from primary cells, but it is unclear whether human cancer cell lines can be reprogrammed. Here we describe the generation and characterization of iPSCs derived from human chronic myeloid leukemia cells. We show that, despite the presence of oncogenic mutations, these cells acquired pluripotency by the expression of 4 transcription factors and underwent differentiation into cell types derived of all 3 germ layers during teratoma formation. Interestingly, although the parental cell line was strictly dependent on continuous signaling of the BCR-ABL oncogene, also termed oncogene addiction, reprogrammed cells lost this dependency and became resistant to the BCR-ABL inhibitor imatinib. This finding indicates that the therapeutic agent imatinib targets cells in a specific epigenetic differentiated cell state, and this may contribute to its inability to fully eradicate disease in chronic myeloid leukemia patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom